Vitiligo, a skin condition causing depigmentation, may significantly increase the risk of serious cardiovascular events.

A recent population-based study from South Korea highlights the long-term dermatological complications linked to COVID-19 ...

Do you have blue eyes? We talked to experts to discover curious facts about baby blues, including whether your biological ...

The regenerative medicine company disappointed its shareholders with a revenue miss that has dragged down full-year results ...

US-based pharmaceutical company VYNE Therapeutics has completed enrolment in the randomised Phase IIb clinical trial of ...

VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial expected in mid-2025"Repibresib" approved as the non-proprietary ...

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report) today and set a price target of ...

VYN201 gel being evaluated in subjects with nonsegmental vitiligoTop-line data from the 24-week double-blind portion of the trial ...

Conventional drug development typically zeroes in on individual proteins or signaling pathways. By focusing on the ...

Opzelura is under clinical development by Incyte and currently in Phase II for Unspecified Dermatological Disorders.

Regenerative medicine focuses on repairing damaged skin and bringing back melanocytes, the cells that give skin its color.

AVITA Medical's Q3 report showed strong sequential sales growth and a lower burn rate. My confidence in it reaching breakeven ...